An Analysis of the Cardiovascular Biomarkers Market: Providing a Valuable Insight...

An Analysis of the Cardiovascular Biomarkers Market: Providing a Valuable Insight into Players, Products and Future Prospects

DUBLIN, Ireland--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/46a3f5/cardiovascular_bio)
has announced the addition of the "Cardiovascular Biomarkers: Players,
Products and Prospects (Volume III)" report to their offering.

Part of our new 3-volume report on Cancer, CNS and Cardiovascular
Biomarkers, this volume provides a comprehensive analysis of the
cardiovascular biomarker sector, along with a critical assessment of
the companies involved.

In 2007, the cardiovascular biomarker market accounted for an
estimated 23% of biomarker revenues to generate over US$1.3 billion
with the majority of revenues derived from biomarker discovery and
molecular diagnostics. The market has yet to reach the maturity of the
oncology biomarker market, but over the coming years the importance of
genetic markers and companion diagnostics will grow. By 2015, the
estimated market value will be US$6.6 billion, with biomarker
discovery being the largest component.

One of the largest markets for cardiovascular biomarkers lies in
the diagnosis of acute coronary syndromes in patients presenting with
acute signs and symptoms, such as shortness of breath or chest pain.

For example, Troponin is well established as a diagnostic marker
of myocardial infarction and has been described as the cornerstone of
diagnosis for the condition. However, the marker has a major
limitation: troponin levels only rise six to eight hours after a
myocardial ischaemia. The search for new diagnostic biomarkers for use
in the acute setting has focused on the identification of earlier
markers of infarction. These include ischaemia modified albumin (IMA)
as well as potential markers, heart fatty acid binding protein and
glycogen phosphorylase isoenzyme BB (GPBB). In addition, some of the
leading providers are suggesting that panels of cardiac markers are
most useful for diagnosis in acute settings. Examples include
Biosite's (now part of Inverness Medical Innovations) CardioProfiler
Triage panel. This is a PoC diagnostic that measures a number of
markers including Troponin I, CK-MB, myoglobin and BNP. New
multi-marker panels are also under development. These include an index
score panel for the diagnosis of peripheral artery disease (VASCLIR,
Vermillion). The panel evaluates (beta)-2-microglobulin, cystatin C,
hsCRP and glucose to create an index score and is currently in
clinical trials.

Screening patients for prediction of future cardiovascular disease
is currently the second major market for cardiovascular biomarkers.
These markers include lipid biomarkers (e.g. LDL, HDL, triglycerides,
LDL particle number and lipoprotein concentrations) or inflammatory
biomarkers (e.g. CRP or Lp-PLA2). Lipid profiles are well-established
as indicators of future cardiovascular risk that can be reduced
through the use of lipid-lowering therapies such as statins.

Questions, Questions

-- What clinical studies are CardioDx currently engaged in?

-- What approach is deCODE Genetics taking in its research?

-- Which pharmaceutical companies are utilising Entelos
predictive biostimulation technology?

Focus on... market potential

In 2007, the cardiovascular biomarker market accounted for and
estimated 23% of biomarker revenues generating over US$1.3 billion,
with the majority of revenues derived from biomarker discovery and
molecular diagnostics. The market has yet to reach the maturity of the
oncology biomarker market, but will grow in the short term with the
introduction of new, proprietary markers for acute coronary syndromes.
Over the coming years, the importance of genetic markers and companion
diagnostics will grow.

By 2015, we estimate the global cardiovascular biomarker market
will account for around one third of global biomarker sales and will
be worth up to US$6.6 billion as it becomes more mature; driven by
growth in clinical biomarkers, the development of targeted therapies
and associated companion diagnostics, discovery and validation of
genetic markers of cardiovascular risk and reimbursement of
pharmacogenomic and prognostic tests.

-0-
*T
Key Topics Covered:

- Cardiovascular Market & Revenues
- Cardiovascular Epidemiology, Diagnosis, Screening & Treatment
- Cardiovascular Biomarkers
- Cardiovascular Biomarker Opportunities & Challenges
- Biomarker Market
- Cardiovascular Biomarker Trends
- Key Biomarker Companies Analysed
- Key Biomarker Evaluation Criteria
- Cardiovascular Biomarkers - Company Analysis

Companies Mentioned:

- Abbott Diagnostics
- Atherotech
- Affymetrix
- Beckman Coulter
- Berkeley HeartLab
- BG Medicine
- CardioDx
- Celera
- CIS Biotech
- Clinical Data
- Compugen
- Critical Diagnostics
- deCODE Genetics
- diaDexus
- Entelos
- FoxHollow Technologies
- GE Healthcare
- Genomas
- Inverness Medical Innovations
- Jurilab
- Laboratory Corporation of America
- Lipomics Technologies
- LipoScience
- Nanosphere Inc
- Osmetech Molecular Diagnostics
- PrognostiX
- Quest Diagnostics
- Roche Diagnostics
- Siemens Medical Solutions
- Singulex
- SuperArray Bioscience Corporation
- Vermillion
- Zora Biosciences OY
*T

For more information visit
http://www.researchandmarkets.com/research/46a3f5/cardiovascular_bio

Source: Espicom Business Intelligence Ltd

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
Fax (USA): 646-607-1907
Fax (International): +353-1-481-1716

Copyright Business Wire 2008